インスリングラルギン (遺伝子組換え) (JP18);
インスリングラルギン (遺伝子組換え) [インスリングラルギン後続1] (JAN);
インスリングラルギン (遺伝子組換え) [インスリングラルギン後続2] (JAN);
Insulin glargine (USAN/INN);
Insulin glargine (genetical recombination) (JP18);
Insulin glargine (genetical recombination) [Insulin glargin biosimilar 1] (JAN);
Insulin glargine (genetical recombination) [Insulin glargin biosimilar 2] (JAN)

ランタス (サノフィ), ランタス (サノフィ), ランタス (サノフィ), ランタス (サノフィ)

BASAGLAR (Eli Lilly and Company), INSULIN GLARGINE (A-S Medication Solutions), INSULIN GLARGINE (Biocon Biologics), INSULIN GLARGINE (Mylan Specialty L.P.), INSULIN GLARGINE (Sanofi-Aventis U.S. LLC), INSULIN GLARGINE (Winthrop U.S), INSULIN GLARGINE (Winthrop U.S.), INSULIN GLARGINE (sanofi-aventis U.S. LLC), INSULIN GLARGINE (sanofi-aventis U.S. LLC), INSULIN GLARGINE SOLOSTAR (A-S Medication Solutions), LANTUS (A-S Medication Solutions), LANTUS SOLOSTAR (A-S Medication Solutions), LANTUS SOLOSTAR (A-S Medication Solutions), REZVOGLAR (Eli Lilly and Company), REZVOGLAR KWIKPEN (A-S Medication Solutions), SEMGLEE (Biocon Biologics), SEMGLEE (Mylan Specialty L.P.), TOUJEO (A-S Medication Solutions), TOUJEO MAX (A-S Medication Solutions)

C267H404N72O78S6

6058.8184

6062.8903

(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Gly
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr
Arg Arg
(Disulfide bridge: A6-A11, A7-B7, A20-B19)

糖尿病治療薬, インスリン受容体作動薬

長時間型インスリンアナログ
持効型溶解インスリンアナログ薬

INSR (CD220) [HSA:3643] [KO:K04527]

CYP induction: CYP1A2 [HSA:1544]
DDI search